Aetiology Based Diagnosis and Treatment Selection in Intellectually Disabled People with Challenging Behaviours

Authors

  • Willem M.A. Verhoeven Vincent van Gogh Institute for Psychiatry, Centre of Excellence for Neuropsychiatry, Venray, The Netherlands
  • Jos I.M. Egger Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, The Netherlands

DOI:

https://doi.org/10.6000/2292-2598.2014.02.02.1

Keywords:

Psychiatric diagnosis, DSM, genetic etiology, psychotropics, pharmacogenetics, behaviour, behavioural phenotype.

Abstract

Since both intellectual disability and challenging behaviour are entities encompassing heterogeneous clinical conditions and current taxonomies are of limited use in this field of psychiatry, diagnosing psychiatric symptoms in intellectually disabled patients is still very complex. In the diagnostic process of psychiatric symptoms and behavioural abnormalities, the first step should be genome profiling using the latest techniques in order to detect pathogenic CNVs or single gene mutations that are causative for the developmental delay. Their importance can be derived from the scientific observation that several genetic syndromes are associated with a specific behavioural, psychiatric, neuropsychological or neurological symptom profile, relevant for both choice of treatment and prognosis. Second, it has to be stressed that psychiatric disorders, especially from the depression and anxiety spectrum, frequently manifest with atypical symptoms that may hamper adequate pharmacological treatment. With respect to challenging behaviours in general, it should be emphasized that these are essentially dependent on contextual variables for which no rational pharmacological treatment is available and behavioural interventions are primarily warranted. Prescription of psychotropics has been demonstrated to be marginally effective only and to induce regularly unwanted side effects or even an increase of abnormal behaviours. It is therefore recommended to measure always the plasma concentration of psychotropics and antiepileptics and to perform, preferably prior to the start of treatment, genotyping of relevant cytochrome isoenzymes.

In is concluded that, apart from the a priori genetic analysis, careful investigation of the here described data sources is needed to formulate a diagnostic hypothesis and treatment proposal.

References

Modinos G, Lyegbe C, Prata D, et al. Molecular genetic gene-environment studies using candidate genes in schizophrenia: a systematic review. Schizophr Res 2013; 150: 356-65. http://dx.doi.org/10.1016/j.schres.2013.09.010

Costain G, Lionel AC, Merico D, et al. Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays. Hum Mol Genet 2013; 22: 4485-501. http://dx.doi.org/10.1093/hmg/ddt297

Seifuddin F, Belmonte Mahon P, Judy J, et al. Meta-analysis of genetic association studies on bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2012; 159B: 508-518. http://dx.doi.org/10.1002/ajmg.b.32057

Elia J, Sackett J, Turner T, et al. Attention-Deficit/Hyperactivity Disorder genomics: update for clinicians. Curr Psychiatry Rep 2012; 14: 579-89. http://dx.doi.org/10.1007/s11920-012-0309-4

Verhoeven WMA, Egger JIM, Feenstra I. Autism and genetic syndromes. In: Deutsch SI, Urbano MR, editors. Autism spectrum disorders: the role of genetics in diagnosis and treatment. Vienna: In Tech 2011; p 31-48. http://dx.doi.org/10.5772/19161

Westen D. Prototype diagnosis of psychiatric syndromes. World Psychiatry 2012; 11: 16-21. http://dx.doi.org/10.1016/j.wpsyc.2012.01.004

Peters ME, Taylor J, Lyketsos CG, Chisolm MS. Beyond the DSM: the perspectives of psychiatry to patients. Prim Care Companion CNS Disord 2012. http://dx.doi.org/10.4088/PCC.11m01233

Batstra L, Frances A. Diagnostic inflation. Causes and a suggested cure. J Nerv Ment Dis 2012; 200: 474-9. http://dx.doi.org/10.1097/NMD.0b013e318257c4a2

Hyman SE. The diagnosis of mental disorders: the problem of reification. Ann Rev Clin Psychol 2010; 6: 155-79. http://dx.doi.org/10.1146/annurev.clinpsy.3.022806.091532

Lyketsos CG, Kozauer N, Rabens PV. Psychiatric manifestations of neurological disease: where are we headed? Dialogues Clin Neurosci 2007; 9: 111-23.

Egger JIM, de Mey H, Janssen G. Assessment of executive functioning in psychiatric disorders: functional diagnosis as the outcome of treatment. Clin Neuropsychiatry 2007; 4: 111-6.

Frances A. The past, present and future of psychiatric diagnosis. World Psychiatry 2013; 12: 111-2. http://dx.doi.org/10.1002/wps.20027

Verhoeven WMA, Tuinier S, van der Burgt I. Top-down or bottom-up: contrasting perspectives on Psychiatric diagnoses. Biologics: Targets & Therapy 2008; 2: 409-17.

Salvador-Carulla L, Reed GM, Vaez-Azizi LM, et al. Intellectual developmental disorders: towards a new name, definition and framework for “mental retardation/intellectual disability” in ICD-11. World Psychiatry 2011; 10: 175-80.

Van Karnebeek CDM, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab 2012; 105: 368-81. http://dx.doi.org/10.1016/j.ymgme.2011.11.191

Maier W, Zobel A. Contribution to allelic variations to the phenotype of response to antidepressants and antipsycho-tics. Eur Arch Psychiatry Clin Neurosci 2008; 258(Suppl 1): 12-20. http://dx.doi.org/10.1007/s00406-007-1004-z

Harrison PJ. The current impact of genetics and genomics on neuropsychopharmacology. Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro. 2013.02.005.

McCarty J, Hemmings C, Kravatrin E, et al. Challenging behavior and co-morbid psychopathology in adults with intellectual disability and autism spectrum disorders. Res Dev Disabil 201; 31: 362-6.

Lundqvist LO. Prevalence and risk markers of behaviour problems among adults with intellectual disabilities: a total population study in Őrebro county. Res Dev Disabil 2013; 34: 1346-56. http://dx.doi.org/10.1016/j.ridd.2013.01.010

Cooper SA, Smiley E, Morrison J, Williamson A, Allan L. An epidemiological investigation of affective disorders with a population-based cohort of 1023 adults with intellectual disabilities. Psychol Med 2007; 37: 873-82. http://dx.doi.org/10.1017/S0033291707009968

Buckles J, Luckasson R, Keefe E. A systematic review of the prevalence of psychiatric disorders in adults with intellectual disability, 2003-2010. J Mental Health Res Intellect Disabil 2013; 6: 181-207. http://dx.doi.org/10.1080/19315864.2011.651682

Aman MG, Burrow WH, Wolford PL. The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes. Am J Ment Retard 1995; 100: 283-92.

Hill J, Pwolitch S, Furniss F. Convergent validity of the aberrant behaviour checklist and behaviour problems inventory with people with complex needs. Res Develop Disabil 2008; 29: 45-60. http://dx.doi.org/10.1016/j.ridd.2006.10.002

Matson JL, Gardner WI, Coe DA, Sovner R. A scale for evaluating emotional disorders in severely and profoundly mentally retarded persons. Development of the Diagnostic Assessment for the Severely Handicapped (DASH) scale. Br J Psychiatry 1991; 159: 404-9. http://dx.doi.org/10.1192/bjp.159.3.404

Paclawskyj T, Matson JL, Bamburg JW, Baglio CS. A comparison of the Diagnostic Assessment for the Severely Handicapped-II (DASH-II) and the Aberrant behaviour Checklist (ABC). Res Dev Disabil 1997; 18: 289-98. http://dx.doi.org/10.1016/S0891-4222(97)00010-3

Moss S, Prosser H, Costillo H, et al. Reliability and validity of the PAS-ADD checklist for detecting psychiatric disorders in adults with intellectual disability. J Intellect Disabil Res 1998; 42: 173-83. http://dx.doi.org/10.1046/j.1365-2788.1998.00116.x

Allan D, Lowe K, Matthews H, Anness Y. Screening for psy-chiatric disorders in a total population of adults with intel-lectual disability and challenging behaviour using the PAS-ADD checklist. J Appl Res Intellect Disabil 2012; 25: 342-9. http://dx.doi.org/10.1111/j.1468-3148.2011.00670.x

Verhoeven WMA, Tuinier S. Neuropsychiatric consultation in mentally retarded patients: a clinical report. Eur Psychiatry 1997; 1: 242-8. http://dx.doi.org/10.1016/S0924-9338(97)83298-1

Battaglia A, Carey JC. Diagnostic evaluation of develop-mental delay/mental retardation: and overview. Am J Med Genet 2003; 177C: 3-14. http://dx.doi.org/10.1002/ajmg.c.10015

Rauch A, Hoyer J, Guth S, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. J Med Genet 2006; 140A: 2063-74. http://dx.doi.org/10.1002/ajmg.a.31416

Pinkel D, Segraves R, Sudar D, et al. High resolution analy-sis of DNA copy number variation using comparative genome hybridization to microarrays. Nat Genet 1998; 20: 207-11. http://dx.doi.org/10.1038/2524

Veltman JA. Genomic microarrays in clinical diagnosis. Curr Opin Pediatr 2006; 18: 598-603. http://dx.doi.org/10.1097/MOP.0b013e3280105417

De Ligt J, Willemsen MH, van Bon BWM, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012; 376: 1921-9. http://dx.doi.org/10.1056/NEJMoa1206524

Gilissen C, Hehir-Kwa JY, Tjwan Thung D, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014. http://dx.doi.org/10.1038/nature13394

Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012; 11: 803-13. http://dx.doi.org/10.1016/S1474-4422(12)70103-5

Veendrick-Meekes MJBM, Verhoeven WMA, van Erp MG, van Blarikom W, Tuinier S. Neuropsychiatric aspects of patients with hypothalamic hamartomas. Epilepsy Behav 2007; 11: 218-21. http://dx.doi.org/10.1016/j.yebeh.2007.03.005

Weintraub D, Buchsbaum R, Resor Jr SR, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007; 10: 105-10. http://dx.doi.org/10.1016/j.yebeh.2006.08.008

Gaitatzis A, Trimble MR, Sander JW. The psychiatric comor-bidity of epilepsy. Acta Neurol Scand 2004; 110: 207-20. http://dx.doi.org/10.1111/j.1600-0404.2004.00324.x

Irwin LG, Fortune DG. Risk factors for psychoses secondary to temporal lobe epilepsy: a systematic review. J Neuropsychiatry Clin Neurosci 2014; 26: 5-23. http://dx.doi.org/10.1176/appi.neuropsych.12120403

Samer CF, Ing Lorenzini K, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013; 17: 165-84. http://dx.doi.org/10.1007/s40291-013-0028-5

Piana C, de Jesus Antunes N, Della Pasqua O. Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs. Expert Opin Drug Metab Toxicol 2014; 10: 341-58. http://dx.doi.org/10.1517/17425255.2014.872630

De Kuijper G, Mulder H, Evenhuis H, Scholte F, Visser F, Hoekstra PJ. Determinants of physical health in individuals with intellectual disability who use long-term antipsychotics. Res Develop Disabil 2013a; 34: 2799-809. http://dx.doi.org/10.1016/j.ridd.2013.05.016

Shogren KA. Considering context: an integrative concept for promoting outcomes in the intellectual disability field. Intellect Dev Disabil 2013; 51: 132-7. http://dx.doi.org/10.1352/1934-9556-51.2.132

Gualtieri CTH. Brain injury and mental retardation: psychopharmacology and neuropsychiatry. Philadelphia: Lippincott Williams & Wilkins; 2002.

Verhoeven WMA, Tuinier S. Cyclothymia or unstable mood disorder? A systematic treatment evaluation with valproic acid. J Appl Res Intellect Disabil 2001; 14: 147-54. http://dx.doi.org/10.1046/j.1468-3148.2001.00063.x

Pinborough-Zimmerman J, Satterfield R, Miller J, Bilder D, Hossain S, McMahon W. Communication disorders: prevalence and comorbid intellectual disability, autism, and emotional/behavioural disorders. Am J Speech Lang Pathol 2007; 16: 359-67. http://dx.doi.org/10.1044/1058-0360(2007/039)

Boyle CA, Boulet S, Schieve LA, et al. Trends in the prevalence of developmental disabilities in US children, 1997-2008. Pediatrics 2011; 127: 1034-42. http://dx.doi.org/10.1542/peds.2010-2989

Yang L, Zhan GD, Ding JJ, et al. Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects – a meta analysis. Plos One 2013; 8: e72640. http://dx.doi.org/10.1371/journal.pone.0072640

Verhoeven WMA, Egger JIM, Ahmed AIA, Kremer BPH, Vermeer S, van de Warrenburg BPC. Cerebellar cognitive affective syndrome and autosomal recessive spastic ataxia of Charlevoix-Saguenay: a report of two male sibs. Psychopathology 2012; 45: 193-9. http://dx.doi.org/10.1159/000331319

Shprintzen RJ. Velo-Cardio-Facial Syndrome: a distinctive behavioural phenotype. Ment Retard Dev Disabil Res Rev 2000; 6: 142-7. http://dx.doi.org/10.1002/1098-2779(2000)6:2<142::AID-MRDD9>3.0.CO;2-H

Baker K, Vorstman JAS. Is there a core neuropsychiatric phenotype in 22q11.2 deletion syndrome? Curr Opin Neurol 2012; 25: 131-7. http://dx.doi.org/10.1097/WCO.0b013e328352dd58

Tang SX, Yi JJ, Calkins ME, et al. Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but not undertreated. Psychol Med 2014; doi:10.1017

Niklasson L, Gillberg C. The neuropsychology of 22q11 deletion syndrome. A neuropsychiatric study of 100 individuals. Res Dev Disabil 2010; 31: 185-94. http://dx.doi.org/10.1016/j.ridd.2009.09.001

Verhoeven WMA, Egger JIM, Tuinier S. Thoughts on the behavioural phenotypes in Prader-Willi syndrome and velo-cardio-facial syndrome: a novel approach. Acta Neuropsychiatr 2007; 19: 244-50. http://dx.doi.org/10.1111/j.1601-5215.2007.00202.x

Schneider M, van der Linden M, Menghetti S, Glaser B, Debbané M, Eliez S. Predominant negative symptoms in 22q11.2 deletion syndrome and their associations with cognitive functioning and functional outcome. J Psychiatr Res 2014; 48: 86-93. http://dx.doi.org/10.1016/j.jpsychires.2013.10.010

Zaleski C, Bassett AS, Tam K, Shugar AL, Chow EWC, McPherson E. The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome. Am J Med Genet 2009; 149A: 525-8. http://dx.doi.org/10.1002/ajmg.a.32650

Butcher NJ, Kiehl TR, Hazrati LN, et al. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome. Identification of a novel genetic form of Parkinson Disease and its clinical implications. JAMA Neurol 2013; 70: 1359-66. http://dx.doi.org/10.1001/jamaneurol.2013.3646

McHugh L, Barnes-Holmes Y, Barnes-Holmes D. Perspective-taking as relational responding: a developmental profile. Psychol Rep 2004; 54: 115-44.

Vilardaga R, Estévez A, Levin ME, Hayws SC. Deictic relational responding, empathy, and experiential avoidance as predictors of social anhedonia: further contributions from relational frame theory. Psychol Rec 2012; 62: 409-32.

Fagerberg CR, Graakjaer J, Heinl UD, et al. Heart defects and other features of the 22q11 distal deletion syndrome. Eur J Med Genet 2013; 56: 98-107. http://dx.doi.org/10.1016/j.ejmg.2012.09.009

Wieser R, Fritz B, Ullmann R, et al. Novel rearrangement of chromosome band 22q11.2 causing 22q11 microdeletion syndrome-like phenotype and rhabdoid tumor of the kidney. Hum Mutat 2005; 26: 78-83. http://dx.doi.org/10.1002/humu.20195

Verhoeven W, Egger J, Brunner H, de Leeuw N. A patient with a de novo distal 22q11.2 microdeletion and anxiety disorder. Am J Med Genet 2010; 155A: 392-7.

Koolen DA, Vissers LELM, Pfundt R, de Leeuw N, et al. A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. Nat Genet 2006; 38: 999-1001. http://dx.doi.org/10.1038/ng1853

Zollino M, Orteschi D, Murdolo M, et al. Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. Nat Genet 2012; 44: 636-8. http://dx.doi.org/10.1038/ng.2257

Koolen DA, Sharp AJ, Hurst JA, et al. Clinical and molecular delineation of the 17q21.31 microdeletion syndrome. J Med Genet 2008; 45: 710-20. http://dx.doi.org/10.1136/jmg.2008.058701

Egger JIM, Wingbermühle E, Verhoeven WMA, et al. Hypersociability in the behavioral phenotype of 17q21.31 microdeletion syndrome. Am J Med Genet 2013; 161A: 21-6.

Kleefstra T, Smidt M, Banning MJG, et al. Disruption of the gene Euchromatin Histione Methyl Transferase 1 (Eu-HMTase 1) is associated with the 9q34 subtelomeric deletion syndrome. J Med Genet 2005; 42: 299-306. http://dx.doi.org/10.1136/jmg.2004.028464

Kleefstra T, Brunner HG, Amiel J, et al. Loss-of-function mutations in Euchromatin Histione Methyl Transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Hum Genet 2009; 79: 370-7. http://dx.doi.org/10.1086/505693

Yatsenko SA, Brundage EK, Roney EK, Cheung SW, Chinault AC, Lupski JR. Molecular mechanisms for subtelomeric rearrangements associated with the 9q34.3 microdeletion syndrome. Hum Mol Genet 2009; 18: 1924-36. http://dx.doi.org/10.1093/hmg/ddp114

Willemsen MH, Vulto-van Silfhout, Nillisen WM, et al. Update on Kleefstra syndrome. Mol Syndromol 2011; 2: 202-12.

Verhoeven WMA, Kleefstra T, Egger JIM. Behavioral phenotype in the 9q subtelomeric deletion syndrome: a report about two adult males. Am J Med Genet 2009; 153B: 536-41.

Verhoeven WMA, Egger JIM, Vermeulen K, van de Warrenburg BPC, Kleefstra T. Kleefstra syndrome in three adult patients: further delineation of the behavioural and neurological phenotype shows aspects of a neurode-generative course. Am J Med Genet 2011; 155A: 2409-15. http://dx.doi.org/10.1002/ajmg.a.34186

Starkstein SE, Leentjes AFG. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008; 79: 1088-92. http://dx.doi.org/10.1136/jnnp.2007.136895

Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand 2013; 127(Suppl 441): 1-47. http://dx.doi.org/10.1111/acps.12038

Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus pallidus und der Substantia nigra. Z Gesammte Neurol Psychiatr 1922; 79: 254-302. http://dx.doi.org/10.1007/BF02878455

Van Craenenbroeck A, Gebruers M, Martin JJ, Cras PC. Hallervorden-Spatz disease: historical case presentation in the spotlight of nosological evolution. Mov Disord 2010; 25: 2486-92. http://dx.doi.org/10.1002/mds.23217

Kruer MC, Boddaert N, Schneider SA, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. Am J Neuroradiol 2012; 33: 407-14. http://dx.doi.org/10.3174/ajnr.A2677

Saitsu H, Nishimura T, Muramatsu K, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet 2013; 45: 445-9. http://dx.doi.org/10.1038/ng.2562

Hayflick SJ, Kruer MC, Gregory A, et al. Beta-propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 2013; 136: 1708-17. http://dx.doi.org/10.1093/brain/awt095

Horvath R. Brain iron takes off: a new propeller protein links neurodegeneration with autophagy. Brain 2013; 136: 1687-91. http://dx.doi.org/10.1093/brain/awt098

Haack TB, Hogarth P, Gregory A, Prokisch H, Hayflick SJ. BPAN: the only X-linked dominant NBIA disorder. Int Rev Neurobiol 2013; 110: 85-90. http://dx.doi.org/10.1016/B978-0-12-410502-7.00005-3

Verhoeven WM, Egger JI, Koolen D, et al. Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: novel mutations and neuropsychiatric phenotype in three adult patients. Parkinsonism Relat Disord 2014; 20: 332-6. http://dx.doi.org/10.1016/j.parkreldis.2013.11.019

Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Sandubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007; 30: 631-41. http://dx.doi.org/10.1007/s10545-007-0661-4

Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010; 5: 16. http://dx.doi.org/10.1186/1750-1172-5-16

Verhoeven WMA, Csepán R, Marcelis CLM, et al. Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia. Acta Pychiatr Scand 2010; 122: 162-5. http://dx.doi.org/10.1111/j.1600-0447.2009.01521.x

Wijburg FA, Wegrzyn G, Burton BK, Tylki-Szymaríska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr 2013; 102: 462-70. http://dx.doi.org/10.1111/apa.12169

Meins W. Wie werden geistig behinderte Erwachsene mit depressiven Störungen psychopharmakologisch behandelt? Nervenarzt 1996; 67: 216-8.

Engel C, Szrama E, Hässler F. Die psychopharmakologische Therapie von Menschen mit geistiger Behinderung. Ein Vergleich der Jahre 1991 und 2005. Psychiat Prax 2010; 37: 391-6. http://dx.doi.org/10.1055/s-0030-1248500

Paton C, Flynn A, Shingleton-Smith A, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J Intellect Disabil Res 2011; 55: 665-74. http://dx.doi.org/10.1111/j.1365-2788.2011.01421.x

Sohanpal SK, Deb S, Thomas C, Soni R, Lenôtre L, Unwin G. The effectiveness of antidepressant medication in the management of behavioural problems in adults with intellectual disabilities: a systematic review. J Intellect Disabil Res 2007; 51: 750-65. http://dx.doi.org/10.1111/j.1365-2788.2006.00935.x

Deb S, Chaplin R, Sohanpal S, Unwin G, Soni R, Lenotre L. The effectiveness of mood stabilizers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: a systematic review. J Intellect Disabil Res 2008; 52: 107-13.

Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 2010; 7: 258-63. http://dx.doi.org/10.1016/j.nurt.2010.04.001

Politte L, McDougle C. Atypical antipsychotics in the treat-ment of children and adolescents with pervasive develop-mental disorders. Psychopharmacology 2014; 231: 1023-36. http://dx.doi.org/10.1007/s00213-013-3068-y

Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2010; 1: CD005040.

Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD) Cochrane Database Syst Rev 2012; 5: CD009043.

Thomson A, Maltezos S, Paliokosta E, Xenitidis K. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Cochrane Database Syst Rev 2010; 2: CD007011.

Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recom-mendations from the British association for psycho-pharmacology. J Psychopharmacol 2014; 28: 179-203. http://dx.doi.org/10.1177/0269881113519509

Loy JH, Merray SN, Hetrick SE, Stasiak K. Atypical antipsyc-hotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev 2012; 9: CD008559.

Pringsheim T, Gorman D. Second-generation antipsychotics for the treatment of disruptive behaviour disorders in chil-dren: a systematic review. Can J Psychiatry 2012; 57: 722-7.

De Hert M, Dobbelaere M. Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26: 144-158. http://dx.doi.org/10.1016/j.eurpsy.2010.09.011

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, de Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A systematic review and meta-analysis. Schizophr Bull 2013; 39: 306-18. http://dx.doi.org/10.1093/schbul/sbr148

Leonhard K. Classification of endogenous psychoses and their differentiated etiology. 2nd ed. Wien: Springer Verlag; 1999. http://dx.doi.org/10.1007/978-3-7091-6371-9

Clarke D, Boer H, Webb T, et al. Prader-Willi syndrome and psychotic symptoms: I. Case descriptions and genetic studies. J Intell Disabil Res 1998; 42: 440-50. http://dx.doi.org/10.1046/j.1365-2788.1998.4260440.x

Verhoeven WMA, Curfs LMG, Tuinier S. Prader-Willi syndrome and cycloid psychosis. J Intellect Disabil Res 1998; 42: 455-62. http://dx.doi.org/10.1046/j.1365-2788.1998.4260455.x

Vogels A, Matthijs G, Legius E, Devriendt K, Fryns JP. Chromosome 15 maternal uniparental disomy and psychosis in Prader-Willi syndrome. J Med Genet 2003; 40: 72-3. http://dx.doi.org/10.1136/jmg.40.1.72

Verhoeven WMA, Tuinier S, Curfs LMG. Prader-Willi syndrome: the psychopathological phenotype in uniparental disomy. J Med Genet 2003; 40: e112. http://dx.doi.org/10.1136/jmg.40.10.e112

Verhoeven WMA, Tuinier S. Prader-Willi syndrome: atypical psychoses and motor dysfunctions. Int Rev Neurobiol 2006; 72: 119-30. http://dx.doi.org/10.1016/S0074-7742(05)72007-9

Larson FV, Whittington J, Webb T, Holland AJ. A longitudinal follow-up study of people with Prader-Willi syndrome with psychosis and those at increased risk of developing psychosis due to genetic subtype. Psychol Med 2013; doi:10.1017.

Tyrer P, Oliver-Africano P, Ahmed Z, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomized controlled study. Lancet 2008; 371: 57-63. http://dx.doi.org/10.1016/S0140-6736(08)60072-0

Ahmed Z, Fraser W, Kerr MP, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry 2000; 176: 42-6. http://dx.doi.org/10.1192/bjp.176.1.42

De Kuijper G, Mulder H, Evenhuis H, Visser F, Hoekstra PJ. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. J Clin Psychopharmacol 2013b; 33: 520-4. http://dx.doi.org/10.1097/JCP.0b013e3182905d6a

De Kuijper G, Evenhuis H, Minderaa RB, Hoekstra PJ. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J Intellect Disabil Res 2014; 58: 71-83. http://dx.doi.org/10.1111/j.1365-2788.2012.01631.x

Caley CF. Interpreting and applying CYP450 genomic test results to psychotropic medications. J Pharm Pract 2011; 24: 439-66. http://dx.doi.org/10.1177/0897190011422873

Ravyn D, Ravyn V, Lowney R, Nasrallah HA. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res 2013; 149: 1-14. http://dx.doi.org/10.1016/j.schres.2013.06.035

Hassiotis A, Robotham D, Canagasabey A, et al. Rando-mized, single-blind, controlled trial of a specialist behaviour therapy team for challenging behaviour in adults with intellectual disabilities. Am J Psychiatry 2009; 166: 1278-85. http://dx.doi.org/10.1176/appi.ajp.2009.08111747

Oliver-Africano P, Murohy D, Tyrer P. Aggressive behaviour in adults with intellectual disability. Defining the role of drug treatment. CNS Drugs 2009; 23: 903-13. http://dx.doi.org/10.2165/11310930-000000000-00000

Sturmey P. Treatment of psychopathology in people with intellectual and other disabilities. Can J Psychiatry 2012; 57: 593-600.

Willner P, Rose J, Jahoda A, et al. Group-based cognitive-behavioural anger management for people with mild to moderate intellectual disabilities: cluster randomised controlled trial. Brit J Psychiatry, 2013; 203: 288-96. http://dx.doi.org/10.1192/bjp.bp.112.124529

Gould E, Trabox J, O’Hora D, Noone S, Bergstrm R. Teaching children with autism a basic component skill of perspective thinking. Behav Intervent 2011; 26: 50-66. http://dx.doi.org/10.1002/bin.320

Wingbermühle E. Egger JIM, Verhoeven WMA, van den Burgt I, Kessels RPC. Affective functioning and social cogni-tion in Noonan syndrome. Psychol Med 2012; 42: 419-26. http://dx.doi.org/10.1017/S0033291711001115

Janssen G, De Mey H, Hendriks A, et al. Assessing deictic relational responding in adults with social anxiety disorder: evidence of perspective taking difficulties. Psychol Rec 2014; 64, 21-9. http://dx.doi.org/10.1007/s40732-014-0013-3

Gladson S, Clarke DJ. Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: benefits and risks. J Intellect Disabil Res 2005; 49: 567-70. http://dx.doi.org/10.1111/j.1365-2788.2005.00708.x

Briegel W. Deletion 22q11.2 und schizophrene Störungen im Kindes- und Jugendalter. Z. Kinder-Jugendpsychiatr Psychother 2007; 35: 353-8. http://dx.doi.org/10.1024/1422-4917.35.5.353

Krahn LE, Maraganore DM, Michels VV. Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22. Mayo Clin Proc 1998; 73: 956-9. http://dx.doi.org/10.4065/73.10.956

Yacoub A, Aybar M. Response to clozapine in psychoses associated with velo-cardio-facial syndrome. Psychiatry 2007; 4: 14.

Gagliano A, Masi G. Clozapine-aripiprazole association in a 7-year-old girl with schizophrenia: clinical efficacy and successful management of neutropenia with lithium. J Child Adolesc Psychopharmacol 2009; 19: 595-8. http://dx.doi.org/10.1089/cap.2009.0012

Sporn A, Addington A, Reiss AI, et al. 22q11 Deletion syndrome in childhood onset schizophrenia: an update. Mol Psychiatry 2004; 9: 225-6. http://dx.doi.org/10.1038/sj.mp.4001477

Müller UJ, Fellgiebel A. Successful treatment of long-lasting psychosis in a case of 22q11.2 deletion syndrome. Pharmacopsychiatry 2008; 41: 158-9. http://dx.doi.org/10.1055/s-2008-1062700

Lin CE, Hwang KS, Hsieh PH, Chi CH. Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1141-3. http://dx.doi.org/10.1016/j.pnpbp.2010.05.011

Carandang CG, Scholten MC. Metyrosine in psychosis associated with 22q11.2 deletion syndrome: case report. J Child Adolesc Psychopharmacol 2007; 17: 115-20. http://dx.doi.org/10.1089/cap.2006.0013

Downloads

Published

2014-09-26

How to Cite

Verhoeven, W. M., & Egger, J. I. (2014). Aetiology Based Diagnosis and Treatment Selection in Intellectually Disabled People with Challenging Behaviours. Journal of Intellectual Disability - Diagnosis and Treatment, 2(2), 83–93. https://doi.org/10.6000/2292-2598.2014.02.02.1

Issue

Section

General Articles